Empire City Laboratories, INC

Empire City Laboratories, INC was paid $142.98M by Medicaid between Jan 2018 and Dec 2024, across 429 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 20% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in New York

Rank by total paid#2 of 116

Median peer was paid$618K

This provider vs. median231×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	1,428,236	$16.69M
2019	1,682,636	$17.36M
2020	1,646,963	$22.34M
2021	2,384,439	$31.35M
2022	2,387,384	$24.44M
2023	2,358,180	$19.03M
2024incomplete	1,731,175	$11.78M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	20%	438,782	393,959	$28.23M
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	5.4%	36,051	34,947	$7.72M
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	4.7%	420,748	399,648	$6.66M
80050	General health panel	3.7%	266,124	263,084	$5.24M
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	3.6%	327,574	295,812	$5.16M
86769		3.4%	154,971	150,669	$4.87M
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	3.1%	133,063	128,377	$4.37M
86481		3.0%	132,588	131,668	$4.28M
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	2.7%	281,118	277,234	$3.84M
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	2.6%	275,252	271,459	$3.75M
83036	Hemoglobin; glycosylated (A1C)	2.1%	624,878	606,637	$3.07M
80061	Lipid panel	2.0%	736,486	724,075	$2.90M

417 more codes

80053	Comprehensive metabolic panel	1.9%	536,256	$2.78M
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	1.8%	240,389	$2.55M
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	1.5%	107,943	$2.17M
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	1.5%	21,170	$2.09M
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	1.3%	114,947	$1.90M
84443	Thyroid stimulating hormone (TSH)	1.3%	370,570	$1.85M
87634		1.2%	117,743	$1.75M
82607		1.1%	233,768	$1.64M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	1.0%	156,942	$1.50M
84439		1.0%	319,949	$1.46M
86317		<1%	171,743	$1.39M
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	606,779	$1.27M
81001		<1%	667,870	$1.22M
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	96,556	$1.21M
87581		<1%	75,861	$1.08M
86803		<1%	172,478	$1.03M
87486		<1%	75,864	$1.02M
87340		<1%	177,150	$1.02M
84153		<1%	105,716	$1.02M
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	50,892	$983K
82746		<1%	143,447	$963K
86003		<1%	21,440	$961K
86762		<1%	92,883	$790K
84481		<1%	138,584	$770K
82728		<1%	104,217	$746K
86765		<1%	91,932	$701K
83013		<1%	15,626	$615K
86708		<1%	104,012	$609K
84403		<1%	40,303	$598K
84154		<1%	54,370	$591K
82652		<1%	33,424	$563K
87086	Culture, bacterial; quantitative colony count, urine	<1%	129,137	$560K
88175	Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer	<1%	33,992	$560K
84466		<1%	85,226	$548K
86696		<1%	63,134	$544K
83655		<1%	73,889	$536K
87507		<1%	3,024	$533K
86704		<1%	92,805	$503K
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	<1%	29,003	$479K
82043		<1%	158,715	$443K
86735		<1%	83,868	$436K
87517		<1%	19,154	$432K
86592		<1%	215,024	$432K
86709		<1%	76,101	$426K
84402		<1%	29,789	$418K
87070		<1%	88,415	$402K
86480		<1%	11,281	$397K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	20,142	$395K
81514		<1%	5,628	$394K
86787		<1%	74,469	$385K
88305	Level IV - Surgical pathology, gross and microscopic examination	<1%	6,858	$384K
86409		<1%	9,786	$383K
86695		<1%	55,653	$383K
88120		<1%	2,477	$382K
83540		<1%	115,896	$334K
84550		<1%	123,916	$317K
84270		<1%	30,725	$316K
87536		<1%	4,307	$293K
82570		<1%	115,150	$284K
87077		<1%	57,639	$282K
87088		<1%	55,507	$262K
87186		<1%	57,836	$252K
82670		<1%	15,071	$236K
88377		<1%	1,133	$230K
83001		<1%	21,867	$229K
84146		<1%	19,899	$222K
80048	Basic metabolic panel (calcium, ionized)	<1%	54,118	$219K
83970		<1%	9,871	$214K
84702		<1%	28,940	$200K
83002		<1%	19,147	$199K
80076		<1%	62,298	$199K
87350		<1%	34,242	$196K
86707		<1%	32,806	$188K
86780		<1%	24,858	$187K
88342		<1%	2,365	$184K
86376		<1%	23,886	$182K
87799		<1%	2,141	$174K
81479	Unlisted molecular pathology procedure	<1%	656	$173K
88313		<1%	2,858	$163K
84378		<1%	24,117	$160K
87522	Neg quan hep c or qual rna	<1%	5,940	$158K
88112		<1%	8,376	$155K
80074		<1%	6,206	$155K
83516		<1%	11,740	$153K
84480		<1%	127,266	$148K
86800		<1%	19,495	$143K
84436		<1%	128,451	$142K
82627		<1%	11,931	$139K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	25,782	$137K
82785		<1%	19,162	$133K
86235		<1%	8,178	$127K
84144		<1%	11,551	$124K
86141		<1%	20,842	$121K
85027		<1%	62,969	$114K
82105		<1%	24,884	$114K
84445		<1%	4,541	$111K
87481		<1%	1,911	$109K
80299		<1%	5,832	$104K
82977		<1%	33,824	$101K
86039		<1%	25,992	$92K
83020		<1%	11,738	$90K
83525		<1%	14,678	$87K
86618		<1%	9,233	$87K
82465		<1%	42,285	$85K
86706		<1%	15,663	$85K
82274		<1%	30,139	$84K
86431		<1%	28,579	$81K
86617		<1%	5,222	$79K
86225		<1%	18,881	$75K
83735		<1%	26,278	$74K
84100		<1%	27,551	$74K
86360		<1%	1,682	$73K
85730		<1%	23,780	$72K
87480		<1%	7,971	$71K
87510		<1%	7,864	$70K
83690		<1%	22,384	$70K
82378		<1%	6,330	$68K
86140		<1%	31,924	$68K
83615		<1%	22,921	$67K
84207		<1%	4,238	$66K
86694		<1%	6,485	$65K
87660		<1%	8,841	$65K
83090		<1%	7,771	$64K
85651		<1%	49,810	$64K
85610		<1%	29,066	$62K
88142		<1%	6,425	$62K
86665		<1%	3,665	$61K
83721		<1%	101,345	$59K
82248		<1%	21,074	$58K
86200		<1%	8,938	$57K
83880		<1%	3,858	$57K
87512		<1%	2,090	$56K
82784		<1%	6,602	$56K
87631		<1%	974	$55K
80184		<1%	7,587	$54K
83520		<1%	6,855	$53K
82150		<1%	19,538	$53K
86900		<1%	18,322	$49K
86705		<1%	9,746	$46K
86304		<1%	4,126	$44K
82040		<1%	21,699	$43K
82550		<1%	15,453	$43K
87625		<1%	2,929	$43K
0100U		<1%	68	$42K
84305		<1%	4,596	$41K
82533		<1%	5,232	$40K
81226		<1%	699	$40K
82672		<1%	3,575	$39K
87046		<1%	3,774	$38K
84075		<1%	13,661	$37K
82565		<1%	14,231	$37K
83550		<1%	70,661	$37K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	1,489	$35K
84446		<1%	4,506	$34K
85045		<1%	18,445	$34K
36415	Collection of venous blood by venipuncture	<1%	135,572	$34K
84590		<1%	5,247	$33K
82310		<1%	12,273	$31K
86060		<1%	9,938	$30K
86901		<1%	17,153	$30K
84597		<1%	4,063	$30K
86359		<1%	1,748	$29K
86160		<1%	2,668	$29K
88141		<1%	4,829	$29K
87902		<1%	174	$29K
84460		<1%	9,372	$28K
84425		<1%	3,029	$28K
82947		<1%	22,983	$28K
84681		<1%	2,632	$27K
87177		<1%	4,745	$27K
81225		<1%	700	$26K
83992		<1%	5,868	$26K
86038		<1%	7,296	$25K
84479		<1%	85,967	$25K
81401		<1%	737	$25K
87075		<1%	5,287	$25K
86341		<1%	3,555	$24K
88312		<1%	886	$23K
87109		<1%	3,997	$21K
82626		<1%	1,699	$21K
84450		<1%	8,217	$21K
84482		<1%	4,893	$20K
83695		<1%	3,043	$19K
82530		<1%	1,739	$19K
84432		<1%	2,719	$18K
86301		<1%	1,724	$18K
85660		<1%	7,072	$18K
82747		<1%	2,762	$18K
87045		<1%	3,784	$18K
80365		<1%	8,595	$18K
83921		<1%	1,304	$17K
80356		<1%	6,958	$17K
P9604	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge	<1%	5,577	$17K
81227		<1%	644	$16K
80360		<1%	4,619	$15K
84255		<1%	1,487	$15K
80373		<1%	5,358	$15K
86644		<1%	1,821	$15K
80357		<1%	4,902	$15K
86021		<1%	2,189	$15K
80371		<1%	4,898	$15K
80372		<1%	4,894	$15K
80368		<1%	4,907	$15K
80354		<1%	4,883	$15K
83825		<1%	1,850	$15K
82172		<1%	1,246	$14K
87184		<1%	1,973	$14K
86664		<1%	1,693	$14K
80348		<1%	6,856	$14K
85384		<1%	3,573	$14K
81230		<1%	575	$14K
81231		<1%	573	$14K
80332		<1%	2,258	$14K
80369		<1%	2,263	$14K
86663		<1%	1,885	$13K
80321		<1%	2,217	$13K
82247		<1%	8,589	$13K
80361		<1%	6,968	$13K
80338		<1%	2,314	$13K
84132		<1%	8,512	$13K
84478		<1%	5,747	$12K
0099U		<1%	19	$12K
80359		<1%	6,264	$11K
84165		<1%	2,519	$11K
80358		<1%	6,277	$11K
80367		<1%	6,268	$11K
83003		<1%	1,668	$11K
80346		<1%	6,342	$11K
82108		<1%	744	$11K
80353		<1%	6,297	$11K
87205		<1%	5,374	$11K
82679		<1%	1,250	$11K
88271		<1%	147	$10K
82525		<1%	1,651	$10K
86593		<1%	4,638	$10K
87632		<1%	103	$10K
81220	CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants	<1%	47	$10K
82175		<1%	1,166	$10K
81241		<1%	747	$9K
84156		<1%	4,624	$9K
84155		<1%	8,264	$9K
84703		<1%	5,122	$9K
86777		<1%	1,148	$9K
82435		<1%	6,964	$9K
82180		<1%	1,833	$9K
86645		<1%	1,468	$9K
80069		<1%	1,729	$8K
80325		<1%	3,419	$8K
81240		<1%	683	$8K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	<1%	194	$8K
82300		<1%	1,062	$7K
86255		<1%	1,577	$7K
80363		<1%	3,554	$7K
81291		<1%	663	$7K
86008		<1%	750	$7K
80337		<1%	3,357	$7K
85014		<1%	5,765	$7K
81025		<1%	3,460	$7K
80414		<1%	195	$6K
82951		<1%	1,330	$6K
82390		<1%	1,297	$6K
86256		<1%	377	$6K
80324		<1%	2,854	$6K
86334		<1%	575	$6K
84166		<1%	985	$6K
84520		<1%	3,186	$6K
80349		<1%	4,253	$6K
84140		<1%	784	$6K
82542		<1%	689	$6K
88323		<1%	104	$6K
82642		<1%	765	$6K
86671		<1%	843	$5K
84252		<1%	488	$5K
83698		<1%	382	$5K
80370		<1%	2,634	$5K
80333		<1%	2,622	$5K
87324		<1%	1,107	$5K
84311		<1%	4,175	$5K
80362		<1%	2,341	$4K
80335		<1%	2,000	$4K
87081		<1%	1,476	$4K
86300		<1%	289	$4K
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	<1%	44	$4K
88309		<1%	117	$4K
86778		<1%	506	$4K
86147		<1%	228	$4K
86850		<1%	1,244	$4K
80345		<1%	2,390	$4K
84591		<1%	632	$4K
G0145	Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision	<1%	506	$4K
81355		<1%	300	$4K
86774		<1%	450	$4K
80173		<1%	434	$4K
80185		<1%	451	$3K
80175		<1%	436	$3K
80157		<1%	434	$3K
80183		<1%	441	$3K
80203		<1%	441	$3K
85008		<1%	12,671	$3K
88274		<1%	94	$3K
80201		<1%	440	$3K
85379		<1%	618	$3K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	78	$3K
83021		<1%	299	$3K
87449		<1%	916	$3K
82985		<1%	535	$3K
80081		<1%	119	$3K
88307		<1%	117	$3K
87493		<1%	166	$3K
86631		<1%	311	$3K
80164		<1%	386	$2K
87328		<1%	315	$2K
88304		<1%	514	$2K
86738		<1%	175	$2K
84410		<1%	133	$2K
86308		<1%	834	$2K
88108		<1%	185	$2K
86037		<1%	176	$2K
87329		<1%	328	$2K
86015		<1%	451	$2K
87530		<1%	46	$2K
82955		<1%	611	$2K
82103		<1%	282	$2K
83986		<1%	4,005	$2K
82024		<1%	90	$2K
81003		<1%	4,689	$2K
86632		<1%	311	$2K
86335		<1%	133	$2K
86702		<1%	413	$2K
86364		<1%	349	$2K
84295		<1%	975	$2K
82270		<1%	749	$2K
80177		<1%	268	$2K
81374		<1%	65	$1K
86258		<1%	297	$1K
85018		<1%	1,286	$1K
87901		<1%	14	$1K
87427		<1%	213	$1K
G0103	Prostate cancer screening; prostate specific antigen test (psa)	<1%	248	$1K
82088		<1%	55	$1K
0241U	Neonatal screening for hereditary disorders, genomic sequence analysis panel	<1%	19	$1K
86701		<1%	406	$1K
80355		<1%	425	$1K
83718		<1%	477	$1K
85060		<1%	111	$1K
82552		<1%	191	$1K
82681		<1%	73	$1K
87168		<1%	584	$1K
83704		<1%	144	$1K
88311		<1%	120	$1K
88341		<1%	87	$929.66
87209		<1%	196	$878.24
84300		<1%	380	$863.27
87147		<1%	350	$853.47
85007		<1%	9,548	$848.89
88164		<1%	945	$823.74
G0123	Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision	<1%	178	$714.94
87150		<1%	429	$711.37
86146		<1%	26	$695.89
85048		<1%	1,178	$655.92
G9143	Warfarin responsiveness testing by genetic technique using any method, any number of specimen(s)	<1%	13	$633.12
80320		<1%	269	$605.65
84244		<1%	55	$600.83
84630		<1%	120	$596.05
86648		<1%	44	$516.99
85097		<1%	116	$506.19
87426	Infectious agent antigen detection, SARS-CoV-2 (COVID-19)	<1%	21	$476.39
83519		<1%	50	$401.97
80400		<1%	17	$360.40
82330		<1%	98	$358.62
87529		<1%	13	$355.81
82725		<1%	90	$324.20
87804	Infectious agent antigen detection by immunoassay; Influenza, each type	<1%	20	$320.60
84442		<1%	54	$314.07
86162		<1%	30	$305.29
88302		<1%	117	$304.69
82668		<1%	38	$291.63
86757		<1%	14	$258.39
88300		<1%	112	$256.96
83789		<1%	28	$250.94
82952		<1%	164	$215.30
80323		<1%	140	$213.76
80051		<1%	93	$207.87
82157		<1%	12	$202.00
87338		<1%	26	$197.92
87563		<1%	14	$186.20
87076		<1%	39	$185.89
87102		<1%	30	$168.69
81383		<1%	12	$163.71
84560		<1%	55	$149.12
82677		<1%	13	$145.82
83010		<1%	12	$140.51
82553		<1%	29	$138.15
85041		<1%	343	$137.47
82379		<1%	23	$132.70
86677		<1%	20	$115.15
80366		<1%	108	$115.12
80178		<1%	25	$102.42
80352		<1%	115	$102.22
80375		<1%	106	$100.00
84133		<1%	41	$86.40
86231		<1%	14	$79.70
82436		<1%	26	$63.04
80342		<1%	114	$50.00
82340		<1%	12	$48.24
82705		<1%	13	$36.70
80336		<1%	64	$31.40
82950		<1%	12	$28.49
85004		<1%	688	$23.65
82945		<1%	12	$22.06
3044F		<1%	61,258	$1.02
3051F		<1%	4,489	$0.06
3046F		<1%	3,051	$0.02
3052F		<1%	2,510	$0.02
99080		0%	5,041	$0.00
88321		0%	42	$0.00
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	0%	12	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialNISANOV, MICHAEL (DIRECTOR OF OPERATIONS)